|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Massachusetts Eye and Ear Infirmary |
|---|---|
| Information provided by: | Massachusetts Eye and Ear Infirmary |
| ClinicalTrials.gov Identifier: | NCT00559936 |
Purpose
The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.
| Condition | Intervention | Phase |
|---|---|---|
|
Corneal Neovascularization |
Drug: Topical Bevacizumab |
Phase I |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label, Single Group Assignment |
| Official Title: | Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization |
| Estimated Enrollment: | 20 |
| Study Start Date: | February 2007 |
| Estimated Study Completion Date: | July 2008 |
| Estimated Primary Completion Date: | July 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
I: Experimental
Each patient will receive topical Avastin in one eye.
|
Drug: Topical Bevacizumab
1.0% custom made topical Avastin twice a day for three weeks
|
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Leila Smaga | 617-573-4439 | Leila_Smaga@meei.harvard.edu |
| United States, Massachusetts | |
| Massachusetts Eye and Ear Infirmary | Recruiting |
| Boston, Massachusetts, United States, 02114 | |
| Contact: Leila Smaga 617-573-4439 Leila_Smaga@meei.harvard.edu | |
| Principal Investigator: Reza Dana, M.D., MPH | |
| Principal Investigator: | Reza Dana, M.D., MPH | Massachusetts Eye and Ear Infirmary |
More Information
| Responsible Party: | Massachusetts Eye & Ear Infirmary ( Reza Dana, Principal Investigator ) |
| Study ID Numbers: | 06-12-077, 06-12-077 |
| Study First Received: | November 14, 2007 |
| Last Updated: | October 22, 2008 |
| ClinicalTrials.gov Identifier: | NCT00559936 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Corneal Diseases Antineoplastic Agents Eye Diseases Growth Substances Physiological Effects of Drugs Bevacizumab Corneal Neovascularization Angiogenesis Inhibitors |
Pharmacologic Actions Pathologic Processes Therapeutic Uses Metaplasia Neovascularization, Pathologic Angiogenesis Modulating Agents Growth Inhibitors |